

**From:** [LE CURIEUX Frank](#)  
**To:** [Kathryn Guyton](#)  
**Cc:** [Andy Shapiro](#); [Ross, Matthew](#); [Matt Martin](#); [Lauren Zeise](#); [Rusyn, Ivan](#)  
**Subject:** RE: Thanks!  
**Date:** Friday, March 13, 2015 9:00:14 AM

---

Dear Kate, all,

Thanks for the dream-team qualification, that I appreciate particularly as a former basketball player ☺

There is **one reflection** I had after the plenary session on Tuesday, that I would like to share with you:

Considering the key role that the conclusion of sub-group 4 (mechanisms) may now have in some cases (e.g. for upgrading from 2A to 2B), I believe it may be beneficial if sub-group 1 (exposure) would be involved at some point, and possibly before the plenary, in the analysis of the data generated (in vivo) in humans. I am referring to the plenary discussion we had on genotoxicity studies on humans for glyphosate (formulation). But this may also apply to other endpoints. Hope this may be helpful.

Cheers,  
Frank

---

**From:** Kathryn Guyton [<mailto:GuytonK@iarc.fr>]  
**Sent:** 13 March 2015 12:20  
**To:** LE CURIEUX Frank; Matthew Ross; Matt Martin; Lauren Zeise; Rusyn, Ivan  
**Cc:** Andy Shapiro  
**Subject:** Thanks!

Dear Frank,

Thank you for your kind words, and for the (fuzzy) pictures! It was wonderful to have you all in Lyon and I'm glad we managed to have at least one relaxing evening together. Many thanks to Ivan for hosting!

In addition to being the Subgroup 4 "dream team" (Kurt's words!) I also wanted to thank you for your outstanding contributions during the Plenary discussion. We were all impressed that Matt(s) Martin was able to quickly calculate p values for the C-A trend test to aid interpretation of the bioassay data! Moreover, recognising the importance of such analyses for interpretation, Andy is busy incorporating standard statistical analyses that would be run in the IARC Table Builder for all entered bioassay incidence data. The pairwise (Fischer) and trend (Cochran-Armitage) tests would thus be automatically run, albeit it will still be possible to enter results of other analyses (e.g., Poly-3 if survival adjustment is possible). I'll be happy to share this when Andy is ready, and welcome your feedback.

Meantime, we've been hard at work drafting the Lancet Oncology article. I'll send it around to you all soon in a google doc (thank you for that suggestion, Matt!). You can also provide input on a Word file. Comments due Monday COB your time.

Hope you all had a very safe return and that re-entry is going well!

Best,

Kate

---

**From:** frank lecurieux <[frank.lecurieux@echa.europa.eu](mailto:frank.lecurieux@echa.europa.eu)>

**Date:** Friday 13 March 2015 08:16

**To:** Matthew Ross <[MRoss@cvm.msstate.edu](mailto:MRoss@cvm.msstate.edu)>, Kate Guyton <[guytonk@iarc.fr](mailto:guytonk@iarc.fr)>, Matt Martin <[martin.matt@epa.gov](mailto:martin.matt@epa.gov)>, Lauren Zeise <[lxzeise@gmail.com](mailto:lxzeise@gmail.com)>, "Rusyn, Ivan" <[IRusyn@cvm.tamu.edu](mailto:IRusyn@cvm.tamu.edu)>

**Subject:** RE: DZN and GLY: section 6 from sub-group 4

Dear all,

First, may I repeat that it was a real pleasure to meet and work with you for IARC monograph vol 112. I think we made quite a nice team – Thanks ☺

Thanks also for the nice moments we shared during the (little) free time we had in Lyon. As promised, here are two photos taken at Ivan's place on Monday evening. The quality of the photos is not so good but I believe the nice atmosphere of the evening clearly shines through the photos ...

[please forward the photos to Andy, as I don't have his e-mail address]

Greetings from a sunny but chilly (0 deg celcius) Helsinki,

Take care

Frank

Frank Le Curieux

Evaluation - E3

European Chemicals Agency

Annankatu 18, P.O. Box 400, FI-00121 Helsinki, Finland

Tel. +358 9 6861 8505

[frank.lecurieux@echa.europa.eu](mailto:frank.lecurieux@echa.europa.eu)

<http://echa.europa.eu>

The above represents the opinion of the author and is not an official position of the European Chemicals Agency. This email, including any files attached to it, is intended for the use of the individual to whom it is addressed. If you have received this message in error, please notify the author as soon as possible and delete the message.

---

*This message and its attachments are strictly confidential. If you are not the intended recipient of this message, please immediately notify the sender and delete it. Since its integrity cannot be guaranteed, its content cannot involve the sender's responsibility. Any misuse, any disclosure or publication of its content, either whole or partial, is prohibited, exception made of formally approved use.*

---